Erik van den Berg serves as CEO at Memo-Therapeutics AG in Switzerland and previously was CEO at AM-Pharma from 2011 through 2023. He is Chairman of Step Pharma and TargED Therapeutics, board member of AM-Pharma, co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX) and co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk). He was board member of Lead Pharma and the Dutch biotechnology organization and core team member for the awarded €250M Biotech Booster Dutch Growth Fund grant. As Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis (SWX/Euronext: ISON - sold to Integra Lifesciences) and as a Management Consultant at Arthur D. Little. Erik has executed over 20 transactions and partnerships, including a $600M alliance with Pfizer, $290M partnership with Kyowa Kirin and €500M in equity and debt financing for biotechnology companies from seed through IPO, including AM-Pharma’s €163M 2019/20 round and Lava’s $19M (A), $83M (B) and $101M (IPO). Erik holds a Master’s degree in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).